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Nox2 dependent redox-regulation 
of microglial response to amyloid-β 
stimulation and microgliosis in 
aging
Li Geng1,2, Lampson M. fan3, Fangfei Liu1, Colin Smith4 & Jian-Mei Li1,2*
Microglia express constitutively a Nox2 enzyme that is involved in neuroinflammation by the 
generation of reactive oxygen species (ROS). Amyloid β (Aβ) plays a crucial role in Alzheimer’s disease. 
However, the mechanism of Aβ-induced microglial dysfunction and redox-regulation of microgliosis 
in aging remains unclear. In this study, we examined Nox2-derived ROS in mediating microglial 
response to Aβ peptide 1–42 (Aβ42) stimulation in vitro, in aging-associated microgliosis in vivo and in 
post-mortem human samples. Compared to controls, Aβ42 markedly induced BV2 cell ROS production, 
Nox2 expression, p47phox and ERK1/2 phosphorylation, cell proliferation and IL-1β secretion. All 
these changes could be inhibited to the control levels in the presence of Nox2 inhibitor or superoxide 
scavenger. Compared to young (3–4 months) controls, midbrain tissues from wild-type aging mice (20–
22 months) had significantly higher levels of Nox2-derived ROS production, Aβ deposition, microgliosis 
and IL-1β production. However, these aging-related changes were reduced or absent in Nox2 knockout 
aging mice. Clinical significance of aging-associated Nox2 activation, microgliosis and IL-1β production 
was investigated using post-mortem midbrain tissues of humans at young (25–38 years) and old age 
(61–85 years). In conclusion, Nox2-dependent redox-signalling is crucial in microglial response to Aβ42 
stimulation and in aging-associated microgliosis and brain inflammation.
Microglial cells are the resident immune cells of the central nervous system (CNS) and play an important role in 
neuroinflammatory responses and the development of aging-related neurodegenerative diseases1,2. Microglial 
cells express constitutively an O2.− generating Nox2 (also called gp91phox) containing NADPH oxidase3. When 
the cells face challenges from pathophysiological insults, the microglial NADPH oxidase is activated and pro-
duces large amount of ROS as a part of the immuno-defence responses to protect the CNS and in the meantime 
causes inflammatory damage to brain tissue4. Microglial cells can also respond to intrinsic metabolic neurotoxic 
by-products or protein aggregates, such as amyloid-β (Aβ) peptide, and become activated. This process can be 
long-lived, self-perpetuating and play a key role in driving the progression of age-related neurodegenerative dis-
eases such as Alzheimer’s disease (AD)5.
One of the pathological characteristics of AD is the extracellular deposition of the Aβ peptide into amyloid 
fibril plaques6,7. Aβ (1–42) fragment (Aβ42) is the dominant Aβ species found in amyloid plaques of AD patients8. 
Microglia display proinflammatory phenotype in contact with Aβ to phagocytose and digest Aβ for its clearance 
and to build up a barrier to prevent neurotoxic effects of Aβ plaques9,10. Increased NADPH oxidase activity was 
found in the brain tissues of animal models of neurodegenerative diseases11–14 and in post-mortem brains of AD 
patients15,16. Inhibition or knockout of Nox2 significantly reduced aging-associated metabolic disorders and brain 
oxidative stress and preserved locomotor function in aging mice17,18. Microglia derived from Nox2 knockout 
(Nox2KO) mice had no ROS response to neurotoxin stimulation19. However, the role of Nox2-derived ROS and 
redox-signalling in mediating microglial response to Aβ stimulation and microgliosis in normal aging remains 
unclear.
In this study we investigated the role of Nox2-derived ROS and the key redox-signalling pathways in medi-
ating microglial response to Aβ42 stimulation in vitro. The crucial role of Nox2 in normal aging-associated 
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oxidative stress, microgliosis, ERK1/2 activation, protein tyrosine nitridation and inflammatory cytokine (IL-
1β) production was examined using midbrain tissues (containing hippocampus and VTA regions) of littermates 
of age-matched wild-type (WT) and Nox2 knockout (Nox2KO) mice at young (3–4 months) and old (20–22 
months) age. Aging-associated Nox2 activation, microgliosis and IL-1β production were further confirmed using 
human post-mortem midbrain samples at young (25–38 years) and old age (61–85 years). Our data provide novel 
information of a crucial role of Nox2 and redox-signalling in mediating microglial response to Aβ42 stimulation 
and aging-associated microgliosis and brain inflammation.
Results
Effects of Aβ42 on BV2 microglial cell ROS production and cell vitality. BV2 cells had been well 
characterized and used as a substitute for primary cells in many previous studies of mouse microglial func-
tions20–22. Therefore, we examined the effects of Aβ42 on BV2 cell O2.− production using lucigenin chemilumi-
nescence in cell suspension (Fig. 1A). Compared to SCP, Aβ42 (24 h) increased markedly the O2.− production by 
BV2 cell in a dose-dependent manner starting at 0.1 µmol/L, peaking at 1 µmol/L and then stayed at a plateau 
form (Fig. 1A, left panel). Time course showed that BV2 cells started to increase ROS production after 10 min of 
Aβ42 stimulation, peaked at ~30 min and remained high up to 2 h of Aβ42 stimulation (Fig. 1A, right panel). The 
effects of Aβ42 on BV2 cell viability was examined by CellTiter 96 AQueous One Solution Cell Proliferation Assay 
(MTS) (Fig. 1B, left panel) and trypan blue exclusion (Fig. 1B, right panel). Aβ42 (24 h) at concentrations ≤ 5 µmol 
promoted BV2 cell proliferation and caused cell death at higher concentrations (Fig. 1B). Aβ42 induced BV2 cell 
proliferation was Nox2-derived ROS dependent and was abolished in the presence of a specific Nox2 inhibitor 
(Nox2tat). The role of ROS in mediating microglial proliferation was further investigated using H2O2 (without 
Aβ42) (Fig. 1C). H2O2 (24 h incubation) used below 100 µM induced BV2 cell proliferation and showed cytotox-
icity above 100 µM.
We also used the traditional MTT assay to examine BV2 cell cytotoxicity in response to Aβ42 (Fig. 1D, 
left panel) and to TNFα (Fig. 1D, right panel). Aβ42 showed  cytotoxicity to BV2 cell at doses above 5 µmol 
(Fig. 1D, left panel). However, different from Aβ42, TNFα showed no cytotoxicity to BV2 cells even at a very high 
dose of 1000 Unit/ml (Fig. 1D, right panel). TNFα-induced BV2 cell proliferation was ROS dependent and could 
be abolished in the presence of tiron, an O2.− scavenger.
The real-time production of O2.− (detected every min for 25 min) by living BV2 cells in response to Aβ42 chal-
lenge (bolus dose, 1 µM) was further examined (Fig. 2A). Aβ42 increased the O2.− production by BV2 cells pro-
gressively with the highest levels at 8–13 minutes of stimulation. Aβ42 induced increase in the O2.− production by 
BV2 cells was completely inhibited by an NADPH oxidase inhibitor, apocynin (20 µmol/L). Compared to control 
cells stimulated with SCP, BV2 cells under Aβ42 stimulation increased ~6-folds of ROS production, which could 
be significantly inhibited by a Nox2 inhibitor (apocynin) or by a flavoprotein inhibitor (DPI) and was abolished 
in the presence of tiron (an O2.− scavenger) or PEG-SOD (a superoxidase dismutase mimic) (Fig. 2B). Aβ42 (1 µM) 
was able to induce BV2 cells O2.− production to a greater extent than PMA (100 ng/ml) and was equivalent to 
TNFα (100 U/ml) (Fig. 2C). Aβ42-induced ROS production by adherent BV2 cell was further confirmed by in situ 
DHE fluorescence (Fig. 2D).
Aβ42 induced Nox2 expression, MAPK activation and Il-1β secretion by BV2 cells. BV2 cell Nox2 
expression and the activation of redox-signalling pathways in response to Aβ42 stimulation were examined firstly 
by Western blots (Fig. 3A). Compared to SCP stimulated control cells, BV2 cells increased significantly the Nox2 
protein expression in response to Aβ42 stimulation (24 h), and this was accompanied with increases in p47phox 
phosphorylation (a key step in Nox2 activation), in expression of microglial ionized calcium binding adaptor 
molecule 1 (Iba-1) and the activation of stress signalling pathways, i.e. ERK1/2 and p38MAPK. Aβ42-induced sub-
cellular expression of Iba-1 (green colour) and p47phox phosphorylation (red colour) were further demonstrated 
by immunofluorescence staining (Fig. 3B). The yellow colour indicated the overlapping of Iba-1 and phos-p47phox 
in Aβ42 stimulated microglial cells predominantly around the perinuclear and plasma membrane regions. Aβ42 
-induced BV2 cell Nox2 expression was also examined by immunofluorescence (Fig. 3C). Accompanied with 
increased Nox2 expression, Aβ42-stimulated BV2 cells displayed visible phagocytic granules in the cytosol.
The effect of Aβ42 (24 h) on BV2 cell IL-1β secretion was examined by ELISA (Fig. 3D). In comparison to SCP 
stimulated cells, Aβ42 increased significantly the levels of IL-1β detected in the culture media of BV2 cells, which 
could be inhibited down to the control level by apocynin, a Nox2 inhibitor, suggesting a regulatory role of Nox2 
in microglial function.
Aging-associated Aβ deposition, microgliosis and Nox2 activation in WT and Nox2KO midbrain 
tissues. Aβ aggregates had been found in aged C57BL/6 mouse brains, which was suggested to be a model to 
study pathogenesis of normal aging-associated Aβ plaque formation23. In order to explore the role of Nox2 and 
ROS in mediating Aβ induced microgliosis and inflammation in aging, we used the midbrain tissue sections of 
WT and Nox2KO mice of the same strain at young (3–4 m) and older age (20–22 m) to examine aging-associated 
Aβ deposition and Nox2 expression by double immunofluorescence (Fig. 4). Compared to their respective young 
controls, both WT and Nox2KO aging brains showed Aβ deposition and plaque formation (red colour). However, 
aging Nox2KO brains had significantly less Aβ deposition in comparison to Aging WT brains (Fig. 4A). WT 
aging brains had remarkably high levels of Nox2 expression (green colour) and a significant proportion of Nox2 
was overlapped with the Aβ plaques (yellow colour) indicating the infiltration of Nox2-positive cells. We then 
examined microglial density and microglial Nox2 expression. Microglia were labelled by Iba-1 (a microglial 
marker, red) and Nox2 was labelled by FITC (green) (Fig. 4B). In comparison with WT young controls, we found 
significant increases in microglial density and Nox2 expression in WT aging brains. The superposed yellow col-
our indicated microglial Nox2 expression. Although the microglial density was also increased in aging Nox2 
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Figure 1. The effects of Aβ42 on BV2 cell ROS production and cell viability. (A) ROS production detected by 
lucigenin-chemiluminescence. Left panel: Aβ42 dose response. Right panel: Aβ42 stimulation time course. Tiron 
was used to confirm the detection of O2.−. (B) Effects of Aβ42 on cell viability detected by MTS assay (left panel) 
or by trypan blue exclusion (right panel). (C) Effects of H2O2 on cell viability detected by MTS assay (left panel) 
or by trypan blue exclusion (right panel). (D) Cell cytotoxicity detected by MTT assay. SCR: scrambled control 
peptide. Nox2tat was used to inhibit Nox2-derived ROS production. n = 5 independent cell cultures. *P < 0.05 
for indicated values versus values at 0 point under the same treatment. †P < 0.05 for indicated values versus Aβ42 
(or TNFα) values without inhibitor in the same treatment group.
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brains, the levels were much less than what were found in WT aging brains (Fig. 4B). Increased expressions of 
Iba-1and Nox2 and increased phosphorylation of p47phox and ERK1/2 in the aging WT (not in aging Nox2KO) 
midbrain tissues were further confirmed by Western blots (Fig. 4C).
Knockout Nox2 reduced brain ROS production, inhibited stress signalling, protein tyros-
ine nitration and IL-1β generation in aging. The levels of brain O2.− production were examined by 
lucigenin-chemiluminescence using midbrain tissue homogenates of WT and Nox2KO mice at young and old age 
(Fig. 5A). Compared to WT young controls, WT aging brains had significantly higher levels of O2.− production, 
which could be reduced to the young control levels by adding apocynin (a Nox2 inhibitor), or DPI (a flavoprotein 
inhibitor) or L-NAME (an eNOS inhibitor), but not by rotenone (mitochondria complex 1 enzyme inhibitor) or 
oxypurinol (xanthine oxidase inhibitor) (Fig. 5A, right panel). In contrast, there were very low levels of O2.− pro-
duction by the midbrain tissues of Nox2KO mice at both young and old age. Aging-associated increase in ROS 
production in the aging WT brains was further examined by in situ DHE fluorescence using midbrain sections 
(Fig. 5B). Although the levels of ROS production in Nox2KO aging brains were also increased in comparison to 
Nox2KO young brains, the levels of increase were much lower than the levels detected in WT aging brains (Fig. 5B).
Superoxide reacts rapidly with NO to form peroxynitrite, a potent electrophile that forms stable 3-nitrotyrosine 
(3-NTyr) adducts of proteins that can be detected by immunofluorescence24. We detected the levels of protein 
tyrosine nitration using antibodies against 3-nitrotyrosin (3-NT) on midbrain sections (Fig. 5C). We found that 
accompanied with increased Nox2-derived O2.− production, there were marked increases in the levels of protein 
nitration detected in the midbrains of aging WT mice but not in aging Nox2KO midbrains (Fig. 5C). Along with 
increased oxidative stress and protein nitration, there were increases in ERK1/2 activation (Fig. 5D) and in the 
levels of IL-1β production (Fig. 5E) detected in the WT aging brains. However, these aging-associated changes 
were significantly reduced in the absence of Nox2.
Studies of human post-mortem midbrain tissues at young and old ages. The clinical significance 
of Nox2 activation in aging-associated microgliosis and inflammation was examined using post-mortem mid-
brain tissues (including the hippocampus and the VTA) of human adults at young (25–38 years old) and old age 
(61–85 years old) without diagnosed neurodegenerative diseases. Tissues were obtained from the UK Medical 
Figure 2. Effects of Nox2 inhibitors or activators on BV2 cell O2.− production detected by lucigenin-
chemiluminescence (A–C) and DHE fluorescence (D). (A) Real-time recording of BV2 cell O2.− production. 
(B) Effect of Nox2 inhibitors, apocynin (Apo) and DPI on Aβ42-induced O2.− production. Tiron and PGE-
SOD were used to scavenge O2.−. (C) Comparison of the effects of Aβ42 (1 µM), PMA (100 ng/ml) and TNFα 
(100 U/ml) on BV2 cell O2.− production. (D) In situ ROS production by adherend BV2 cells detected by DHE 
fluorescence. n = 5 independent cell culture experiments. *P < 0.05 for indicated values versus SCP values 
(A,B,D) or control values (C). †P < 0.05 for indicated values versus Aβ42 values (B) or values without ROS 
scavenger (D) in the same treatment group.
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Research Council (MRC) tissue bank. Compared to young controls, aged human midbrain tissue had high levels 
of O2.− production, which could be inhibited down to the young control levels in the presence of a Nox2 inhibitor, 
apocynin (Fig. 6A). Increased ROS production by human aging brains was further confirmed by increased lipid 
peroxidation detected using MDA assay (Fig. 6B). Along with increased ROS production, there were significant 
increases in brain production of inflammatory cytokine, IL-1β (Fig. 6C); in microglial density (labelled by Iba-1, 
red) and Nox2 expression (green) (Fig. 6D). The yellow color in the merged images indicated microglial Nox2 
expression (Fig. 6D). The aging brains had remarkable levels of p47phox phosphorylation (labelled green) and activa-
tion of stress signaling pathway, ERK1/2 (labelled in red) (Fig. 6E). The representative H&E staining showed visible 
white-matters in the midbrain sections of aging individuals in comparison to the sections of young adults (Fig. 6E).
Discussion
Microglial dysfunction and increased ROS production by Nox2 enzyme are hallmarks of age-related neurode-
generative diseases2,4. Aβ42 is the dominant peptide found in AD plaques8. Microglia have been found adherent to 
Aβ plaques and to phagocytose Aβ in post-mortem brains of AD patients9,10. The current study using series of in 
vitro cytological and biochemistry assays, plus experiments using midbrain samples of age-matched littermates of 
Figure 3. Aβ42-induced Iba-1 and Nox2 expression, the activation of stress-signalling pathways and IL-1β 
secretion by BV2 cells. (A) Western blots. Optical densities (ODs) of protein bands were quantified and 
normalized to β-actin (loading control) detected in the same sample. (B) p47phox phosphorylation (red) was 
detected using a phosphorylation specific antibody against p47phox (Ser359) and double stained with antibody 
against Iba-1 (green) by immunofluorescence. (C) Nox2 expression (red) detected by immunofluorescence. Nuclei 
were labelled by DAPI (blue) to visualise the cells. Fluorescence intensities were quantified, and expressed as index 
against controls without primary antibody. (D) IL-1β detected in the culture media by ELISA. n = 5 independent 
cell cultures. *P < 0.05 for indicated values versus SCP values. †P < 0.05 for indicated values versus Aβ42 values.
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WT and Nox2KO mice at young (3–4 m) and aging (20–22 m) and post-modem human midbrain tissues at young 
(25–38 years) and old age (61–85 years) provides evidences for the first time that: (1) Nox2-dependemnt ROS and 
redox-signalling regulated microglial responses to Aβ42 stimulation; (2) Knockout or inhibition of Nox2 protects 
aging brains from oxidative stress, microgliosis and IL-1β secretion.
Figure 4. Aging-associated Aβ deposition and microglia proliferation in the midbrain tissues of WT and Nox2KO mice. 
(A) Immunofluorescence detection of Aβ deposition (red) and Nox2 expressions (green). (B) Immunofluorescence 
detection of microglia (labelled with Iba-1, red) and Nox2 (green). Fluorescence intensities were quantified, and 
expressed as index against control slides without primary antibody. Nuclei were labelled with DAPI (blue) to visualize 
the cells. (C) Western blot. Optical densities (ODs) of protein bands were quantified and normalized to β-actin detected 
in the same samples. n = 9 mice/per group. *P < 0.05 for indicated values versus young values of the same genetic group. 
†P < 0.05 for indicated values versus WT values of the same age group.
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Different from pathogen-induced oxidative burst described for neutrophils or blood monocytes25, we found 
that Aβ42 -induced BV2 microglia cell ROS production is a progressive reaction that needed around 10 min to 
reach the peak and lasts for hours. Along with increased ROS production, microglial cell proliferated in response 
to Aβ42 stimulation, which was inhibited in the presence of either Nox2 inhibitor or O2.− scavenger. TNFα had 
been shown to induce microglial proliferation through its action on NADPH oxidase and ROS production26,27. 
It was suggested that Aβ-induced microglial proliferation was via the release of TNFα. In the current study, 
we found that both Aβ42 and TNFα were able to induce BV2 microglial proliferation. However, different from 
TNFα that is produced and released by microglia into the local extracellular environment, Aβ is phagocytosed 
by microglial cells and is cytotoxic at higher doses and could eventually kill microglial cells. Although BV-2 had 
been extensively characterized and used widely as a substitute for primary microglia in many experimental set-
tings20, limitation should be considered when interpreting quantitative data obtained from BV2 cells. However, 
Figure 5. Aging-associated increase in ROS production, stress signalling activation and IL-1β production in 
the midbrain tissue of WT and Nox2KO mice. (A) O2.− production detected by lucigenin-chemiluminescence 
using brain homogenates (left panels) and the effects of different enzyme inhibitors on WT aging brain ROS 
production (right panel). (B) In situ ROS production by midbrain sections detected using DHE fluorescence. 
(C) Protein tyrosine nitration detected using antibody against 3-NT by immunofluorescence on midbrain 
sections. 3-NT fluorescence intensity were quantified and expressed as % of WT young controls (expressed 
as 100%). (D) Aging associated ERK1/2 phosphorylation (red colour) detected using phos-ERK1/2 specific 
antibodies. (E) Levels of IL-1β detected in the midbrain tissue homogenates by ELISA. n = 9 mice/per group. 
*P < 0.05 for indicated values versus young values of the same genetic group, or values without inhibitor (A, 
right panel). †P < 0.05 for indicated values versus WT values of the same age group.
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in the current study, the Nox2 activation and redox-regulation of microgliosis and IL-1 production in aging were 
confirmed by in vivo model of WT and Nox2KO mice and by using human brain samples at young and old age.
Previously, Aβ aggregates had been found in the brain tissues of aged WT C57BL/6 mice, and was suggested 
to be a model to study Aβ plaque formation in normal aging23. In addition, WT mice increased brain Aβ con-
centration when subjected to repeated mechanical stress or inflammation28. Adding to the existing literature, 
we showed in this study that Aβ deposition could be detected in the midbrain tissues of aging C57BL/6 mice 
Figure 6. Aging-associated Nox2 activation, microgliosis and IL-1β production in post-mortem human 
midbrain tissues at young (25–38 years); and old age (61–85 years). (A) O2.− production detected by lucigenin-
chemiluminescence. (B) Lipid peroxidation detected by MDA assay. (C) Brain IL-1β levels detected by ELISA. 
Data were presented as fold changes against the young control values without inhibitor (expressed as 1). (D) 
Immunofluorescence detection of microglia density (labelled by Iba-1, red) and Nox2 expression (green). The 
yellow colour in merged images indicated the microglial expression of Nox2. (E) Immunofluorescence detection 
of p47phox (green) and ERK1/2 (red) phosphorylation. Single channel fluorescence intensities were quantified. 
Young n = 7 and aging n = 8. *P < 0.05 for indicated values versus young values. †P < 0.05 for indicated values 
versus values without inhibitor in the same age group.
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using antibodies against Aβ by immunofluorescence specifically. Although knockout of Nox2 could not stop Aβ 
accumulation in the aging brain, the levels of Aβ found in aging Nox2KO midbrains were significantly less than 
in aging WT controls. Under the breeding condition without infection, we did not find any difference in life span 
between aged WT versus Nox2KO mice. In addition, Nox2KO aging brains had markedly less ROS production 
along with reduced levels of protein tyrosine nitration, p47phox and ERK1/2 phosphorylation, microgliosis and 
IL-1β production.
Increased inflammatory cytokine production by activated microglia in the CNS is an indicator of neuroinflam-
mation29,30. Interleukin-1 (IL-1) is one of the major inflammatory cytokines produced by microglia in response 
to Aβ stimulation29. An important finding from the current study is Nox2-derived ROS regulation of microglial 
IL-1β production. Inhibition of Nox2 by apocynin reduced BV2 cell IL-1β secretion in response to Aβ42 stimula-
tion, and knockout of Nox2 completely abolished aging-associated IL-1β production in the mid-brain tissue. The 
clinical significance of Nox2-derived ROS in aging associated microglial dysfunction was further demonstrated 
using post-mortem midbrain tissues of young (25–38 years old) and elderly (61–85 years old) adults without 
diagnosed neurodegenerative diseases. We showed that along with an increased brain ROS production, there 
were markedly up-regulations of microglial density, microglial Nox2 expression, phosphorylation of p47phox and 
ERK1/2, and IL-1β production in the aging human midbrain tissues. Limitation should be considered when 
detecting lipid peroxidation by MDA in post-mortem human brain tissues due to the non-specificity of the 
assay or other possible issues after brain death31. However, in the current study, complementary technique of 
lucigenin-chemiluminescence with or without Nox2 inhibitor was also applied to measure brain ROS production.
In summary, we have presented in this study, by using several complementary approaches (in vitro cell culture, 
aging model of WT and Nox2KO mice, and human post-mortem brain tissues of young and elderly adults), an 
in-depth insight into the mechanisms of Nox2-dependent redox-regulation of microglial response to Aβ42 stim-
ulation and a crucial role of Nox2-derived ROS in ageing-associated oxidative stress, microgliosis and Il-1β pro-
duction. Knockout or inhibition of Nox2-derived ROS production protects brain from aging-associated oxidative 
damage, microglial dysfunction and inflammation.
Materials and Methods
Reagents. Amyloid beta peptide (1–42) (Aβ42) and scrambled control peptide (SCP) were purchased from 
Cambridge Biosciences UK and prepared according to the manufacturer’s instruction. The scrambled control 
peptide (SCP) and Nox2tat ([H]-RKKRRQRRRCSTRVRRQL-[NH2]) were provided by PeptideSynthetics 
(PPR Ltd. Fareham, UK). A mouse microglial cell line (BV-2) was obtained from Banca Biologica e Cell Factory, 
Genova, Italy. IL-1β ELISA (mouse and human) kits were from Thermofisher Scientific (UK). DHE (dihydro-
ethidium) was from Invitrogen (UK). Antibodies against phos-p47phox (Ser359), phos-ERK1/2 (Thr202/Tyr204) 
and 3-nitrotyrosine were from Sigma (UK). Antibodies against Nox2, Iba-1 and Aβ (D-17, sc-5399) were from 
Santa Cruz Biotechnology (UK). Antibodies against phos-p38MAPK (Thr180/Tyr182) was from Cell Signaling 
Technology (UK). All other reagents and chemicals were from Sigma unless stated otherwise in the text.
Animals. The animal studies were performed in accordance with the protocols approved by both the 
University Ethics Committee and the UK Home Office under the Animals Act (Scientific Procedures) 1986, 
UK. Nox2KO mice on a C57BL/6J background were originally obtained from Jackson Laboratories (strain 
B6.129S6-Cybb/J, stock number: 002365), USA. Littermates of WT and Nox2KO mice were bred in our institu-
tion from heterozygotes and genotyped. Animals were housed under standard conditions with a 12:12 light dark 
cycle and food and water were available ad libitum. The midbrain tissues (containing hippocampus and ventral 
tegmental area regions) from littermates of age-matched WT and Nox2KO male mice at young (3–4 month), and 
aging (20–22 month) were used (n = 9/per group) for the experiments.
Human post-mortem midbrain tissues. The post-mortem human midbrain tissues (including hip-
pocampus and the VTA) from individuals (Caucasian ethnical origin) were obtained from the UK Medical 
Research Council Edinburgh Brain & Tissue Bank. This study had ethical approval from the UK National 
Health Service Research Ethical Committee (East of Scotland Ethics Service) and the institutional (University of 
Edinburgh, UK) ethics review board. The inclusive criteria were: adults aged between 25–40 for the young group 
and age > 60 for aging group. The exclusion criteria were: prior medical history of neurodegenerative disease, 
adults aged between 41–60 and visible midbrain abnormalities at autopsy. Brain sample were collected between 
23–126 hours of post-mortem interval; and grouped randomly according to their ages as young (25–38 years, 
n = 7:6 males, 1 female); and elderly (61–85 years, n = 8: 6 male and 2 female).
Cell culture. BV-2 mouse microglial cells were cultured in RPMI-1640 medium supplemented with 
heat-inactivated FBS (10% v/v), L-glutamine (2 mM), streptomycin (100 µg/mL), and penicillin (50 IU/mL). 
The day prior to treatment, cells were detached by trypsin-EDTA solution, counted and seeded at 1 × 105/mL 
medium in 35 mm cell culture dishes. Next day, cells were stimulated with a scrambled control peptide (SCP) 
or with Aβ42 at the same concentration (0.1–10 µM) dissolved in PBS for the periods indicated in the figures. 
For the experiments to detect Nox2 upregulation, activation of signalling pathways and IL-1β production, cells 
were stimulated for 24 h as described previously26,27. PMA (100 ng/ml) and TNFα (100 U/ml) were used (24 h) 
to activate Nox2 enzyme in some experiments. Cells were then detached and counted. Cell pellets were used for 
further experiments.
Cell viability and cytotoxicity assays. Cell viability was examined using CellTiter 96 AQueous One 
Solution Cell Proliferation Assay (MTS) (Promega). Briefly, BV2 cells were seeded in 96-well flat-bottom plates at 
a density of 1 × 104 cells/well the day before experiment. Next day the medium was replaced with 100 µl of 5% FCS 
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medium containing either SCP or Aβ42 at different concentrations (0–10 µM) with or without Nox2tat and incu-
bated for 24 h. The MTS assay reagents were then added according to manufacturer’s instruction and the plates 
were incubated for 1 h. The absorbances at 490 nm were recorded using a plate reader (Molecular Devices, UK).
The Aβ42 toxicity were examined using MTT assay kit (Sigma, UK) according to manufacturer’s instruction. 
Cells were seeded and stimulated with SCP or Aβ42 as described above in phenol red-free culture medium. In 
some experiments, TNFα was used with or without tiron for 24 h proliferation. The medium was then replaced by 
100 µL MTT solution (0.5 mg/mL in phenol red free medium). Following 2 h of incubation, the MTT solution was 
removed and the crystals formed were dissolved with 100 µL of DMSO and the absorbance was read at wavelength 
of 569 nm using a plate reader (Molecular Devices).
ROS measurement. The O2− production by living BV2 cells (5 × 104 cells in suspension) was measured 
by lucigenin (5 μM)-chemiluminescence or by DHE (2 μM) fluorescence for adherent cells cultured onto cham-
ber slides as described previously18. The specificity of O2.− detection was confirmed by adding tiron (10 mM), a 
nonenzymatic O2.− scavenger or polyethylene glycol-adsorbed–superoxide dismutase (PEG-SOD, 100 U/ml), 
a free-radical scavenger. NADPH oxidase inhibitor: apocynin (20 μM) or Nox2tat (10 µM) or a flavo-proteins 
inhibitor, DPI (diphenyleneiodonium, 20 μM) were used to inhibit Nox2 activity. Some experiments were per-
formed using PMA (100 ng/ml) or TNF α (100 U/ml) to activate microglial NADPH oxidase. DHE images were 
captured digitally and acquired using a ZEISS fluorescence microscope (Axio Scope.A1). The fluorescence inten-
sity was quantified from at least 5 random fields (269.7 × 269.2 µm) per section with 3 sections/sample.
Immunofluorescence microscopy. The experiments were performed exactly as described previously18. 
Primary antibodies were used at 1:250 dilution. BSA (2%) was used in the place of primary antibodies as a nega-
tive control. Biotin-conjugated anti-rabbit or anti-goat IgG (1:1000 dilution) were used as secondary antibodies. 
Specific binding of antibodies was detected by extravidin-FITC or streptavidin-Cy3. Images were acquired with 
a ZEISS fluorescence microscope (Axio Scope.A1). Fluorescence intensities were quantified as described above.
Immunoblotting. This was performed exactly as described previously18. The images were captured digitally 
using an ImageQuant LAS 4000 mini imaging system (GE Healthcare, UK), and the optical densities of the pro-
tein bands were normalized to the loading control bands and quantified.
Detection of brain tissue IL-1β and MDA assay. The brain tissue IL-1β levels were measured in mid-
brain tissue homogenates using IL-1β ELISA kits (ThermoFisher, UK) according to manufacturer’s instruction. 
Lipid peroxidation in brain tissue homogenates was detected using MDA assay kit (Sigma-Aldrich, UK) accord-
ing to manufacturer’s instruction.
Statistical analysis. Statistical analysis was performed using one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni post-hoc tests. For experiments using cultured BV2 cells, the assays were performed in 
duplicates and repeated for 3–5 time using independent cell cultures. The animal data were obtained from 9 mice/
group. For human experiments, 7–8 individual midbrain tissues were used per group. Data were expressed as 
mean ± SD except where specified in the figure legends. P < 0.05 was considered statistically significant.
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